| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Peptidase (IMPa) targets peptide bonds in proteins and peptides. It hydrolytically cleaves these bonds, breaking down proteins and peptides into smaller fragments. It does not have a specific pharmacological target but is an enzymatic tool used for protein digestion and peptide bond hydrolysis.
|
|---|---|
| ln Vitro |
In vitro, Peptidase (IMPa) catalyzes the hydrolysis of peptide bonds in proteins and peptides. It is used in biochemical assays to digest proteins or peptides. It is a catalytically active enzyme with activity on various peptide substrates. Its activity can be measured by monitoring the release of amino acids or peptides.
|
| ln Vivo |
In vivo, Peptidase (IMPa) is not typically used as a therapeutic agent. It is a research enzyme. No specific in vivo pharmacological activities are reported. It may be used in studies of protein digestion and metabolism.
|
| Enzyme Assay |
Cell-free enzyme assays for Peptidase (IMPa): the enzyme is incubated with a peptide or protein substrate in appropriate buffer at optimal pH and temperature. The reaction is stopped, and the release of amino acids or peptides is measured using colorimetric (e.g., ninhydrin), fluorometric, or HPLC methods. One unit of enzyme activity is defined based on substrate hydrolysis.
|
| Cell Assay |
Cellular assays for Peptidase (IMPa): cells are not typically treated with this enzyme as it acts on extracellular proteins. The enzyme is used in cell-free systems for protein digestion. No direct cellular effects are reported.
|
| Animal Protocol |
In vivo animal studies for Peptidase (IMPa): the enzyme is not administered to animals as a therapeutic agent. No specific pharmacological studies are reported. It is a research reagent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Peptidase (IMPa): as an enzyme, it is not intended for systemic administration. No systemic pharmacokinetics are applicable. The enzyme is for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity of Peptidase (IMPa): as an enzyme, it is generally well-tolerated. In research settings, the enzyme is considered safe for laboratory use. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Nguyen TTH, et, al. Distributions of Extracellular Peptidases Across Prokaryotic Genomes Reflect Phylogeny and Habitat. Front Microbiol. 2019 Mar 5;10:413.
|
| Additional Infomation |
Peptidase (IMPa) is a research enzyme used for protein and peptide hydrolysis in biochemical assays. It is a microorganism-derived peptidase. Its primary application is in protein digestion and peptide bond cleavage studies. No clinical applications have been reported.
|
| CAS # |
9031-96-3
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
